Autoimmune autonomic ganglionopathy: IgG effects on ganglionic acetylcholine receptor current

Z. Wang, Phillip Anson Low, J. Jordan, R. Freeman, C. H. Gibbons, C. Schroeder, P. Sandroni, S. Vernino

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

BACKGROUND: Autoimmune autonomic ganglionopathy (AAG) is an acquired immune-mediated form of diffuse autonomic failure. Many patients have serum antibodies that bind to the ganglionic acetylcholine receptors (AChRs) that mediate fast synaptic transmission in autonomic ganglia. Previous clinical studies and observations in animal models suggest that AAG is an antibody-mediated neurologic disorder. METHODS: Using whole-cell patch clamp techniques, we recorded ganglionic AChR currents in cultured human IMR-32 cells and examined the effects of bath application of IgG derived from patients with AAG. RESULTS: IgG from seven patients with AAG all produced a progressive decline in whole-cell ganglionic AChR current, whereas IgG from control subjects had no effect. The effect was abolished at low temperature. Fab antibody fragments had no effect unless a secondary antibody was added concurrently. IgG from one patient also produced a more immediate reduction of ganglionic AChR current. CONCLUSIONS: The characteristics of antibody-mediated inhibition of ganglionic acetylcholine receptor (AChR) current are consistent with modulation and blocking of the membrane AChR, analogous to the effects of muscle AChR antibodies in myasthenia gravis. Our observations demonstrate that antibodies in patients with autoimmune autonomic ganglionopathy (AAG) cause physiologic changes in ganglionic AChR function and confirm that AAG is an antibody-mediated disorder.

Original languageEnglish (US)
Pages (from-to)1917-1921
Number of pages5
JournalNeurology
Volume68
Issue number22
DOIs
StatePublished - May 2007

Fingerprint

Cholinergic Receptors
Immunoglobulin G
Antibodies
Autonomic Ganglia
Immunoglobulin Fragments
Immunoglobulin Fab Fragments
Myasthenia Gravis
Patch-Clamp Techniques
Nervous System Diseases
Baths
Synaptic Transmission
Animal Models
Muscles
Temperature
Membranes
Serum

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Wang, Z., Low, P. A., Jordan, J., Freeman, R., Gibbons, C. H., Schroeder, C., ... Vernino, S. (2007). Autoimmune autonomic ganglionopathy: IgG effects on ganglionic acetylcholine receptor current. Neurology, 68(22), 1917-1921. https://doi.org/10.1212/01.wnl.0000263185.30294.61

Autoimmune autonomic ganglionopathy : IgG effects on ganglionic acetylcholine receptor current. / Wang, Z.; Low, Phillip Anson; Jordan, J.; Freeman, R.; Gibbons, C. H.; Schroeder, C.; Sandroni, P.; Vernino, S.

In: Neurology, Vol. 68, No. 22, 05.2007, p. 1917-1921.

Research output: Contribution to journalArticle

Wang, Z, Low, PA, Jordan, J, Freeman, R, Gibbons, CH, Schroeder, C, Sandroni, P & Vernino, S 2007, 'Autoimmune autonomic ganglionopathy: IgG effects on ganglionic acetylcholine receptor current', Neurology, vol. 68, no. 22, pp. 1917-1921. https://doi.org/10.1212/01.wnl.0000263185.30294.61
Wang, Z. ; Low, Phillip Anson ; Jordan, J. ; Freeman, R. ; Gibbons, C. H. ; Schroeder, C. ; Sandroni, P. ; Vernino, S. / Autoimmune autonomic ganglionopathy : IgG effects on ganglionic acetylcholine receptor current. In: Neurology. 2007 ; Vol. 68, No. 22. pp. 1917-1921.
@article{eb8070d11cf9425e8e18351276e8592f,
title = "Autoimmune autonomic ganglionopathy: IgG effects on ganglionic acetylcholine receptor current",
abstract = "BACKGROUND: Autoimmune autonomic ganglionopathy (AAG) is an acquired immune-mediated form of diffuse autonomic failure. Many patients have serum antibodies that bind to the ganglionic acetylcholine receptors (AChRs) that mediate fast synaptic transmission in autonomic ganglia. Previous clinical studies and observations in animal models suggest that AAG is an antibody-mediated neurologic disorder. METHODS: Using whole-cell patch clamp techniques, we recorded ganglionic AChR currents in cultured human IMR-32 cells and examined the effects of bath application of IgG derived from patients with AAG. RESULTS: IgG from seven patients with AAG all produced a progressive decline in whole-cell ganglionic AChR current, whereas IgG from control subjects had no effect. The effect was abolished at low temperature. Fab antibody fragments had no effect unless a secondary antibody was added concurrently. IgG from one patient also produced a more immediate reduction of ganglionic AChR current. CONCLUSIONS: The characteristics of antibody-mediated inhibition of ganglionic acetylcholine receptor (AChR) current are consistent with modulation and blocking of the membrane AChR, analogous to the effects of muscle AChR antibodies in myasthenia gravis. Our observations demonstrate that antibodies in patients with autoimmune autonomic ganglionopathy (AAG) cause physiologic changes in ganglionic AChR function and confirm that AAG is an antibody-mediated disorder.",
author = "Z. Wang and Low, {Phillip Anson} and J. Jordan and R. Freeman and Gibbons, {C. H.} and C. Schroeder and P. Sandroni and S. Vernino",
year = "2007",
month = "5",
doi = "10.1212/01.wnl.0000263185.30294.61",
language = "English (US)",
volume = "68",
pages = "1917--1921",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "22",

}

TY - JOUR

T1 - Autoimmune autonomic ganglionopathy

T2 - IgG effects on ganglionic acetylcholine receptor current

AU - Wang, Z.

AU - Low, Phillip Anson

AU - Jordan, J.

AU - Freeman, R.

AU - Gibbons, C. H.

AU - Schroeder, C.

AU - Sandroni, P.

AU - Vernino, S.

PY - 2007/5

Y1 - 2007/5

N2 - BACKGROUND: Autoimmune autonomic ganglionopathy (AAG) is an acquired immune-mediated form of diffuse autonomic failure. Many patients have serum antibodies that bind to the ganglionic acetylcholine receptors (AChRs) that mediate fast synaptic transmission in autonomic ganglia. Previous clinical studies and observations in animal models suggest that AAG is an antibody-mediated neurologic disorder. METHODS: Using whole-cell patch clamp techniques, we recorded ganglionic AChR currents in cultured human IMR-32 cells and examined the effects of bath application of IgG derived from patients with AAG. RESULTS: IgG from seven patients with AAG all produced a progressive decline in whole-cell ganglionic AChR current, whereas IgG from control subjects had no effect. The effect was abolished at low temperature. Fab antibody fragments had no effect unless a secondary antibody was added concurrently. IgG from one patient also produced a more immediate reduction of ganglionic AChR current. CONCLUSIONS: The characteristics of antibody-mediated inhibition of ganglionic acetylcholine receptor (AChR) current are consistent with modulation and blocking of the membrane AChR, analogous to the effects of muscle AChR antibodies in myasthenia gravis. Our observations demonstrate that antibodies in patients with autoimmune autonomic ganglionopathy (AAG) cause physiologic changes in ganglionic AChR function and confirm that AAG is an antibody-mediated disorder.

AB - BACKGROUND: Autoimmune autonomic ganglionopathy (AAG) is an acquired immune-mediated form of diffuse autonomic failure. Many patients have serum antibodies that bind to the ganglionic acetylcholine receptors (AChRs) that mediate fast synaptic transmission in autonomic ganglia. Previous clinical studies and observations in animal models suggest that AAG is an antibody-mediated neurologic disorder. METHODS: Using whole-cell patch clamp techniques, we recorded ganglionic AChR currents in cultured human IMR-32 cells and examined the effects of bath application of IgG derived from patients with AAG. RESULTS: IgG from seven patients with AAG all produced a progressive decline in whole-cell ganglionic AChR current, whereas IgG from control subjects had no effect. The effect was abolished at low temperature. Fab antibody fragments had no effect unless a secondary antibody was added concurrently. IgG from one patient also produced a more immediate reduction of ganglionic AChR current. CONCLUSIONS: The characteristics of antibody-mediated inhibition of ganglionic acetylcholine receptor (AChR) current are consistent with modulation and blocking of the membrane AChR, analogous to the effects of muscle AChR antibodies in myasthenia gravis. Our observations demonstrate that antibodies in patients with autoimmune autonomic ganglionopathy (AAG) cause physiologic changes in ganglionic AChR function and confirm that AAG is an antibody-mediated disorder.

UR - http://www.scopus.com/inward/record.url?scp=34249779549&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34249779549&partnerID=8YFLogxK

U2 - 10.1212/01.wnl.0000263185.30294.61

DO - 10.1212/01.wnl.0000263185.30294.61

M3 - Article

C2 - 17536048

AN - SCOPUS:34249779549

VL - 68

SP - 1917

EP - 1921

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 22

ER -